As per this study, the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market was valued USD 4.81 BN (by revenue) in 2022 and is anticipated to reach USD 12.09 BN by 2030 with a CAGR of 12.2%.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a chronic hematological disorder, i.e. disorder which primarily affects the blood. It is an ultra-rare disease of bone marrow stem cells which affects more than 20,000 people globally. This disease affects men and women equally. Physical symptoms can begin at any age, they usually develop between 30-40 years of age. The only curative therapy for PNH patients is allogeneic stem cell transplantation.
Market Dynamics
The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of paroxysmal nocturnal hemoglobinuria (PNH) treatment.
Market Segmentation
The broad paroxysmal nocturnal hemoglobinuria (PNH) treatment market has been sub-grouped into treatment. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Treatment
- Medication
- Stem Cell Transplant
- Blood Transfusion
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for paroxysmal nocturnal hemoglobinuria (PNH) treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Region (Representative Graph)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market include Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited (Shire Plc), Akari Therapeutics, Apellis Pharmaceuticals, Ra Pharmaceuticals, Achillion Pharmaceuticals, Amgen Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.